TY - JOUR
AU - Lewis, Jason S.
AB - Intact antibodies and their truncated counterparts (eg, Fab, scFv fragments) are generally exquisitely specific and selective vectors, enabling recognition of individual cancer‐associated molecular phenotypes against a complex and dynamic biomolecular background. Complementary alignment of these advantages with unique properties of radionuclides is a defining paradigm in both radioimmunoimaging and radioimmunotherapy, which remain some of the most adept and promising tools for cancer diagnosis and treatment. This review discusses how translational potency can be maximized through rational selection of antibody‐nuclide couples for radioimmunoimaging/therapy in preclinical models.
TI - Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection
JF - Journal of Labelled Compounds and Radiopharmaceuticals
DO - 10.1002/jlcr.3612
DA - 2018-01-01
UR - https://www.deepdyve.com/lp/wiley/preclinical-optimization-of-antibody-based-radiopharmaceuticals-for-lZzp7g59x9
SP - 611
EP - 635
VL - 61
IS - 9
DP - DeepDyve
ER -